• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $UPXI

    Upexi Inc.

    Subscribe to $UPXI
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    IPO Year: 2021

    Exchange: NASDAQ

    Recent Analyst Ratings for Upexi Inc.

    DatePrice TargetRatingAnalyst
    8/4/2025$15.00Buy
    Alliance Global Partners
    6/16/2025$16.00Neutral → Overweight
    Cantor Fitzgerald
    See more ratings

    Upexi Inc. Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Alliance Global Partners initiated coverage on Upexi, Inc. with a new price target

    Alliance Global Partners initiated coverage of Upexi, Inc. with a rating of Buy and set a new price target of $15.00

    8/4/25 8:09:26 AM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    Upexi, Inc. upgraded by Cantor Fitzgerald with a new price target

    Cantor Fitzgerald upgraded Upexi, Inc. from Neutral to Overweight and set a new price target of $16.00

    6/16/25 7:42:40 AM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    Upexi Inc. Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Salkind Gene bought $100,000 worth of shares (20,243 units at $4.94) and was granted 200,000 shares, increasing direct ownership by 60% to 585,370 units (SEC Form 4)

    4 - UPEXI, INC. (0001775194) (Issuer)

    7/30/25 4:47:19 PM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    Director Dugan Lawrence bought $97,770 worth of shares (16,000 units at $6.11) and was granted 100,000 shares, increasing direct ownership by 29,820% to 116,389 units (SEC Form 4)

    4 - UPEXI, INC. (0001775194) (Issuer)

    7/24/25 4:05:17 PM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    Chief Executive Officer Marshall Allan bought $799,998 worth of shares (161,943 units at $4.94) and was granted 1,200,000 shares, increasing direct ownership by 154% to 2,246,261 units (SEC Form 4)

    4 - UPEXI, INC. (0001775194) (Issuer)

    7/24/25 4:03:08 PM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    Chief Executive Officer Marshall Allan bought $1,500,001 worth of shares (657,895 units at $2.28) and was granted 75,000 shares, increasing direct ownership by 484% to 884,318 units (SEC Form 4)

    4 - UPEXI, INC. (0001775194) (Issuer)

    4/25/25 4:01:36 PM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    Chief Financial Officer Norstrud Andrew James bought $100,001 worth of shares (43,860 units at $2.28) and was granted 100,000 shares, increasing direct ownership by 942% to 159,138 units (SEC Form 4)

    4 - UPEXI, INC. (0001775194) (Issuer)

    4/25/25 4:01:26 PM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    Director Salkind Gene bought $550,002 worth of shares (241,229 units at $2.28), increasing direct ownership by 195% to 365,127 units (SEC Form 4)

    4 - UPEXI, INC. (0001775194) (Issuer)

    4/25/25 4:01:17 PM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    Marshall Allan bought $44,739 worth of shares (77,773 units at $0.58), increasing direct ownership by 3% to 2,939,654 units (SEC Form 4)

    4 - UPEXI, INC. (0001775194) (Issuer)

    3/18/24 4:55:17 PM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    Marshall Allan bought $72,109 worth of shares (103,013 units at $0.70), increasing direct ownership by 4% to 2,861,881 units (SEC Form 4)

    4 - UPEXI, INC. (0001775194) (Issuer)

    3/6/24 3:04:50 PM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    Marshall Allan bought $12,340 worth of shares (12,916 units at $0.96), increasing direct ownership by 0.47% to 2,767,249 units (SEC Form 4)

    4 - UPEXI, INC. (0001775194) (Issuer)

    12/20/23 1:37:18 PM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    Marshall Allan bought $84,952 worth of shares (90,001 units at $0.94), increasing direct ownership by 3% to 2,754,333 units (SEC Form 4)

    4 - UPEXI, INC. (0001775194) (Issuer)

    12/7/23 2:42:38 PM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    Upexi Inc. Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Salkind Gene bought $100,000 worth of shares (20,243 units at $4.94) and was granted 200,000 shares, increasing direct ownership by 60% to 585,370 units (SEC Form 4)

    4 - UPEXI, INC. (0001775194) (Issuer)

    7/30/25 4:47:19 PM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    CSO Rudick Brian Benjamin was granted 400,000 shares, increasing direct ownership by 91% to 838,597 units (SEC Form 4)

    4 - UPEXI, INC. (0001775194) (Issuer)

    7/24/25 4:09:34 PM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    Director Dugan Lawrence bought $97,770 worth of shares (16,000 units at $6.11) and was granted 100,000 shares, increasing direct ownership by 29,820% to 116,389 units (SEC Form 4)

    4 - UPEXI, INC. (0001775194) (Issuer)

    7/24/25 4:05:17 PM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    Director Williams Thomas Charles was granted 100,000 shares (SEC Form 4)

    4 - UPEXI, INC. (0001775194) (Issuer)

    7/24/25 4:03:45 PM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    Chief Executive Officer Marshall Allan bought $799,998 worth of shares (161,943 units at $4.94) and was granted 1,200,000 shares, increasing direct ownership by 154% to 2,246,261 units (SEC Form 4)

    4 - UPEXI, INC. (0001775194) (Issuer)

    7/24/25 4:03:08 PM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    Chief Financial Officer Norstrud Andrew James was granted 250,000 shares, increasing direct ownership by 157% to 409,138 units (SEC Form 4)

    4 - UPEXI, INC. (0001775194) (Issuer)

    7/24/25 4:02:25 PM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    New insider Rudick Brian Benjamin claimed ownership of 438,597 shares (SEC Form 3)

    3 - UPEXI, INC. (0001775194) (Issuer)

    6/3/25 6:04:17 AM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    Chief Executive Officer Marshall Allan bought $1,500,001 worth of shares (657,895 units at $2.28) and was granted 75,000 shares, increasing direct ownership by 484% to 884,318 units (SEC Form 4)

    4 - UPEXI, INC. (0001775194) (Issuer)

    4/25/25 4:01:36 PM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 4 filed by Director Williams Thomas Charles

    4 - UPEXI, INC. (0001775194) (Issuer)

    4/25/25 4:01:45 PM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    Chief Financial Officer Norstrud Andrew James bought $100,001 worth of shares (43,860 units at $2.28) and was granted 100,000 shares, increasing direct ownership by 942% to 159,138 units (SEC Form 4)

    4 - UPEXI, INC. (0001775194) (Issuer)

    4/25/25 4:01:26 PM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    Upexi Inc. Press Releases

    Fastest customizable press release news feed in the world

    View All

    Upexi Reports Record Digital Asset Revenue for Fiscal First Quarter 2026

    Digital Asset Revenue was Approximately $6.1 Million for the Quarter Gross Profit Totaled $8.3 Million, up 183% Year-Over-Year Net Income Increased to $66.7 Million, Compared to a Net Loss of $1.6 Million, Year-over-Year Conference Call Scheduled for today, November 11, 2025, at 5:30 p.m. Eastern Time TAMPA, Fla., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Upexi, Inc. (NASDAQ:UPXI) ("Upexi" or the "Company"), a leading Solana-focused digital asset treasury company and consumer brands owner, today announced record digital asset revenue for the fiscal first quarter ended September 30, 2025. Financial Highlights for the Quarter Ended September 30, 2025 Total revenue for the quarter was $9.2 mill

    11/11/25 5:25:00 PM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    Clear Street's Disruptive Technology Conference Convenes this Month in Palm Beach

    Invitation-only event features CEOs, investors and innovators across AI, Digital Assets, Fintech and beyond Keynote speakers Michael Saylor and Eric Trump highlight lineup of thought leaders NEW YORK and PALM BEACH, Fla., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Clear Street, ("Clear Street", "the Company") a cloud-native financial infrastructure technology firm on a mission to give sophisticated investors access to every asset in every market, will host its Disruptive Technology Conference on November 19–20, 2025, at the Four Seasons Resort Palm Beach, Florida. The two-day, invitation-only event brings together a select group of CEOs, institutional investors and pioneering industry leaders fo

    11/7/25 2:30:00 PM ET
    $ABTC
    $BKKT
    $CLSK
    EDP Services
    Technology
    Finance: Consumer Services
    Finance

    Upexi to Host First Quarter 2026 Earnings Call on November 11th at 5:30 p.m. ET

    TAMPA, Fla., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Upexi, Inc. (NASDAQ:UPXI) (the "Company" or "Upexi"), a leading Solana-focused digital asset treasury company and consumer brands owner, today announced that it plans to host a conference call and report its financial results for the first quarter 2026 ended September 30, 2025, on Tuesday, November 11, 2025. Additional details are available under the Investor Relations section of the Company's website: https://ir.upexi.com/ Event:Upexi First Quarter 2026 Earnings CallDate:Tuesday, November 11, 2025Time:5:30 p.m. ETLive Call:1-877-407-9716 (U.S. Toll-Free) or 1-201-493-6779 (International)Webcasthttps://ir.upexi.com/news-events/ir-calendar Fo

    11/6/25 8:00:00 AM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    Key Metrics Demonstrate Upexi's Proven Shareholder Value Creation

    Metrics include a $72 million unrealized gain1, an 82% increase in adjusted SOL per share, and a 96% investor return on the April equity private placement TAMPA, Fla., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Upexi, Inc. (NASDAQ:UPXI), a leading Solana-focused digital asset treasury company and consumer brands owner, today released its periodic update. "Upexi remains positioned to grow despite reduced treasury company sentiment," stated Upexi CEO Allan Marshall. "Whether via a large unrealized gain, a substantial increase in adjusted SOL per share, or the strong performance of our stock since embarking on our Solana treasury strategy, we remain committed to creating long-term incremental value

    11/4/25 8:00:00 AM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    Upexi to Participate in Upcoming November Investor Conferences

    TAMPA, Fla., Oct. 31, 2025 (GLOBE NEWSWIRE) -- Upexi, Inc. (NASDAQ:UPXI) (the "Company" or "Upexi"), a leading Solana-focused digital asset treasury company and consumer brands owner, today announced that management will participate in the following November 2025 investor conferences. Details for each conference can be found below. The link to webcasted presentations can be found on our Investor Relations website here: https://ir.upexi.com/news-events/ir-calendar. New Orleans Investment ConferenceDate: November 2-5, 2025Location: Hilton New Orleans Riverside, New Orleans, LAAttendees: Brian Rudick, Chief Strategy OfficerType: Booth and Presentation Presentation Date and Time: Tuesday, Nov

    10/31/25 8:00:00 AM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    Upexi Welcomes Jon Najarian to the Upexi Advisory Committee

    TAMPA, Fla., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Upexi, Inc. (NASDAQ:UPXI), a brand owner specializing in the development, manufacturing, and distribution of consumer products with diversification into the cryptocurrency space, today announced the addition of Jon Najarian (Twitter: @jonnajarian) to the Upexi Advisory Committee, joining Arthur Hayes and S◎L Big Brain as founding Upexi Advisory Committee members. Jon Najarian is a highly influential figure in the world of finance, renowned for his deep expertise in options trading and market strategy. A former professional football player, Jon co-founded options trading firm Mercury Trading and later launched financial education company Marke

    10/23/25 8:00:00 AM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    Upexi to Participate in Upcoming October Investor Conferences

    TAMPA, Fla., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Upexi, Inc. (NASDAQ:UPXI) (the "Company" or "Upexi"), a brand owner specializing in the development, manufacturing, and distribution of consumer products with diversification into the cryptocurrency space, today announced that management will participate in the following October 2025 investor conferences. Conference details can be found below for each. A.G.P.'s Digital Asset Treasury ShowcaseDates: October 8, 2025Location: VirtualAttendees: Brian Rudick, Chief Strategy OfficerType: Fireside Chat Fireside Chat Date and Time: Wednesday, October 8, 2025, at 11:00 am E.T. Webcast: https://ir.upexi.com/news-events/ir-calendar Planet Microcap Show

    10/6/25 8:00:00 AM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    Upexi Welcomes SOL Big Brain to the Upexi Advisory Committee

    TAMPA, Fla., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Upexi, Inc. (NASDAQ:UPXI), a brand owner specializing in the development, manufacturing, and distribution of consumer products with diversification into the cryptocurrency space, today announced the addition of S◎L Big Brain (Twitter: @SOLBigBrain) to the Upexi Advisory Committee, joining Arthur Hayes as founding Upexi Advisory Committee members. S◎L Big Brain stands at the very heart of the Solana ecosystem – an indispensable force driving culture, influence, and vision. Playing key roles at MonkeDAO and BigBrainVC, S◎L Big Brain champions transformation, amplifies voice, and cultivates community with unparalleled reach and enduring influen

    9/30/25 8:00:00 AM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    Upexi Reports Financial Results for Fiscal Year Ended June 30, 2025 and Provides Shareholders with Solana Treasury Update Since June 30, 2025

    TAMPA, Fla., Sept. 24, 2025 (GLOBE NEWSWIRE) -- Upexi, Inc. (NASDAQ:UPXI) (the "Company" or "Upexi"), a brand owner specializing in the development, manufacturing, and distribution of consumer products with diversification into the cryptocurrency space, today announced its financial results for the fiscal year ended June 30, 2025. The annual report is available on either the SEC's website or on Upexi's IR website. Financial Highlights for the Fiscal Year ended June 30, 2025: Revenue totaled $15.8 million.Gross profit totaled approximately $10.7 million, representing a gross margin of 67%.Net loss totaled approximately $13.7 million.As of September 10, 2025, there are 58,893,261 shares of

    9/24/25 5:55:38 PM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    Upexi Adjusted SOL per Share Increases 129% Since Treasury Launch

    Unrealized gain now stands at $142 million1 TAMPA, Fla., Sept. 11, 2025 (GLOBE NEWSWIRE) -- Upexi, Inc. (NASDAQ:UPXI), a brand owner specializing in the development, manufacturing, and distribution of consumer products with diversification into the cryptocurrency space, today released its periodic update. "The last several weeks were extremely strong for Upexi, highlighted by a substantial increase in the price of SOL," stated Upexi CEO Allan Marshall. "As a result, our Solana treasury now stands at $447 million, including an unrealized gain of $142 million. Moreover, we continued to expand our visibility, welcoming Arthur Hayes to our newly-established Advisory Committee, and met with m

    9/11/25 8:00:00 AM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    Upexi Inc. SEC Filings

    View All

    Upexi Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - UPEXI, INC. (0001775194) (Filer)

    11/12/25 4:06:12 PM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 10-Q filed by Upexi Inc.

    10-Q - UPEXI, INC. (0001775194) (Filer)

    11/12/25 6:10:19 AM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 424B3 filed by Upexi Inc.

    424B3 - UPEXI, INC. (0001775194) (Filer)

    11/10/25 6:14:21 AM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 424B3 filed by Upexi Inc.

    424B3 - UPEXI, INC. (0001775194) (Filer)

    11/10/25 6:13:32 AM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    Upexi Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - UPEXI, INC. (0001775194) (Filer)

    11/7/25 5:01:35 PM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    Upexi Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - UPEXI, INC. (0001775194) (Filer)

    11/5/25 5:01:52 PM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    Upexi Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - UPEXI, INC. (0001775194) (Filer)

    10/24/25 5:20:56 PM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    Amendment: SEC Form S-1/A filed by Upexi Inc.

    S-1/A - UPEXI, INC. (0001775194) (Filer)

    10/20/25 5:08:01 PM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    Amendment: SEC Form S-1/A filed by Upexi Inc.

    S-1/A - UPEXI, INC. (0001775194) (Filer)

    10/20/25 5:09:39 PM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SCHEDULE 13G filed by Upexi Inc.

    SCHEDULE 13G - UPEXI, INC. (0001775194) (Subject)

    10/16/25 10:36:03 AM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    Upexi Inc. Leadership Updates

    Live Leadership Updates

    View All

    Upexi Welcomes Jon Najarian to the Upexi Advisory Committee

    TAMPA, Fla., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Upexi, Inc. (NASDAQ:UPXI), a brand owner specializing in the development, manufacturing, and distribution of consumer products with diversification into the cryptocurrency space, today announced the addition of Jon Najarian (Twitter: @jonnajarian) to the Upexi Advisory Committee, joining Arthur Hayes and S◎L Big Brain as founding Upexi Advisory Committee members. Jon Najarian is a highly influential figure in the world of finance, renowned for his deep expertise in options trading and market strategy. A former professional football player, Jon co-founded options trading firm Mercury Trading and later launched financial education company Marke

    10/23/25 8:00:00 AM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    Upexi Establishes Advisory Committee and Welcomes Arthur Hayes as First Member

    Additional members to join the Advisory Committee in the coming weeks to optimize performance, increase visibility and unlock capital raising opportunities Arthur brings deep expertise, exposure and connectivity to both digital assets and traditional finance TAMPA, Fla., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Upexi, Inc. (NASDAQ:UPXI) (the "Company" or "Upexi"), a brand owner specializing in the development, manufacturing and distribution of consumer products with diversification into the cryptocurrency space, today announced the establishment of the Upexi Advisory Committee, composed of highly prominent individuals from the digital assets and traditional finance industries. Upexi will seek t

    8/12/25 8:00:00 AM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    Upexi Inc. Financials

    Live finance-specific insights

    View All

    Upexi Reports Record Digital Asset Revenue for Fiscal First Quarter 2026

    Digital Asset Revenue was Approximately $6.1 Million for the Quarter Gross Profit Totaled $8.3 Million, up 183% Year-Over-Year Net Income Increased to $66.7 Million, Compared to a Net Loss of $1.6 Million, Year-over-Year Conference Call Scheduled for today, November 11, 2025, at 5:30 p.m. Eastern Time TAMPA, Fla., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Upexi, Inc. (NASDAQ:UPXI) ("Upexi" or the "Company"), a leading Solana-focused digital asset treasury company and consumer brands owner, today announced record digital asset revenue for the fiscal first quarter ended September 30, 2025. Financial Highlights for the Quarter Ended September 30, 2025 Total revenue for the quarter was $9.2 mill

    11/11/25 5:25:00 PM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    Upexi to Host First Quarter 2026 Earnings Call on November 11th at 5:30 p.m. ET

    TAMPA, Fla., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Upexi, Inc. (NASDAQ:UPXI) (the "Company" or "Upexi"), a leading Solana-focused digital asset treasury company and consumer brands owner, today announced that it plans to host a conference call and report its financial results for the first quarter 2026 ended September 30, 2025, on Tuesday, November 11, 2025. Additional details are available under the Investor Relations section of the Company's website: https://ir.upexi.com/ Event:Upexi First Quarter 2026 Earnings CallDate:Tuesday, November 11, 2025Time:5:30 p.m. ETLive Call:1-877-407-9716 (U.S. Toll-Free) or 1-201-493-6779 (International)Webcasthttps://ir.upexi.com/news-events/ir-calendar Fo

    11/6/25 8:00:00 AM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    Upexi Reports Financial Results for Fiscal Year Ended June 30, 2025 and Provides Shareholders with Solana Treasury Update Since June 30, 2025

    TAMPA, Fla., Sept. 24, 2025 (GLOBE NEWSWIRE) -- Upexi, Inc. (NASDAQ:UPXI) (the "Company" or "Upexi"), a brand owner specializing in the development, manufacturing, and distribution of consumer products with diversification into the cryptocurrency space, today announced its financial results for the fiscal year ended June 30, 2025. The annual report is available on either the SEC's website or on Upexi's IR website. Financial Highlights for the Fiscal Year ended June 30, 2025: Revenue totaled $15.8 million.Gross profit totaled approximately $10.7 million, representing a gross margin of 67%.Net loss totaled approximately $13.7 million.As of September 10, 2025, there are 58,893,261 shares of

    9/24/25 5:55:38 PM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    Upexi Purchases 83,000 SOL, Grows Treasury to 1.9 Million SOL Worth $381 Million

    TAMPA, Fla., July 23, 2025 (GLOBE NEWSWIRE) -- Upexi, Inc. (NASDAQ:UPXI) (the "Company" or "Upexi"), a brand owner specializing in the development, manufacturing and distribution of consumer products with diversification into the cryptocurrency space, today announced the acquisition of 83,000 SOL for $16.7 million, or $201.34 per SOL. The purchase brings the Company's holdings to 1.9 million SOL worth over $381 million using the $200.60 spot price of Solana as of 5:00 pm ET yesterday. Allan Marshall, Chief Executive Officer of Upexi, remarked, "The U.S. continues to make progress around digital asset legislation, which has the potential to usher in mass adoption of blockchain technology.

    7/23/25 8:00:00 AM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    Upexi Grows Treasury to 1.819 Million SOL Worth $331 Million with a $58 Million Unrealized Gain in Under Three Months

    Upexi purchased an additional 100,000 SOL, and anticipates it may generate up to approximately $26 million in annual staking revenue based on current SOL holdingsCompany releases adjusted metrics for enhanced transparency and analysis TAMPA, Fla., July 21, 2025 (GLOBE NEWSWIRE) --  Upexi, Inc. (NASDAQ:UPXI) (the "Company" or "Upexi"), a brand owner specializing in the development, manufacturing and distribution of consumer products with diversification into the cryptocurrency space, today announced the acquisition of 100,000 SOL, bringing its treasury holdings to 1,818,809 SOL worth $331 million. The recent purchase follows the successful closing of a roughly $200 million equity and c

    7/21/25 8:00:00 AM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    Upexi Regains Compliance with NASDAQ

    Filing Form 10-K for the Year Ended June 30, 2024Filing Form 10-Q for the Quarter Ending September 30, 2024 TAMPA, FL / ACCESSWIRE / December 23, 2024 / Upexi, Inc. (NASDAQ:UPXI) (the "Company" or "Upexi"), a brand owner specializing in the development, manufacturing and distribution of consumer products, announced its financial results for the year ended June 30, 2024 and the first quarter ending September 30, 2024 last week. On November 20, 2024 the Company received written notice (the "Compliance Notice") from Nasdaq informing the Company that it has regained compliance with Nasdaq Listing Rule 5250( c)(1) (the "Rule"). The Staff had concluded that with the filing of these two periodic re

    12/23/24 9:00:00 AM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    Upexi Reports Fiscal Second Quarter 2024 Financial Results

    TAMPA, FL / ACCESSWIRE / February 14, 2024 / Upexi, Inc. (NASDAQ:UPXI) (the "Company" or "Upexi"), a multi-faceted Amazon and Direct to Consumer brand owner and innovator in aggregation, today reported its financial results for the fiscal second quarter 2024 ending December 31, 2023."During the quarter we continued to focus on optimizing and streamlining our operations, investing in our higher margin Brand Products and generating positive Adjusted EBITDA. While revenue for the most recent fiscal second quarter decreased sequentially, the operating measures we took allowed us to increase gross profit margins to 38%, as compared to the prior fiscal first quarter of 31.8%. We also generated pos

    2/14/24 4:05:00 PM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    Upexi to Host Fiscal 2024 Second Quarter Financial Results Conference Call on February 14th at 4:30 PM ET

    TAMPA, FL / ACCESSWIRE / February 12, 2024 / Upexi Inc. (NASDAQ:UPXI) (the "Company" or "Upexi"), a multi-faceted Amazon and Direct-to-Consumer brand owner and innovator in aggregation, today announced it will host a conference call on Wednesday, February 14, 2024 at 4:30 p.m. ET, to discuss its financial results for the fiscal 2024 second quarter and provide a business update.Financial Results Conference CallEvent:Fiscal 2024 Second Quarter Financial Results Conference CallDate:Wednesday, February 14, 2024Time:4:30 p.m. Eastern TimeLive Call:1-877-407-9716 (U.S. Toll Free) or 1-201-493-6779 (International)Webcast:https://ir.upexi.com/news-events/ir-calendarFor those unable to join the confe

    2/12/24 9:00:00 AM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    Upexi Revenue Increases 144% Year-Over-Year and 53.5% Sequentially to $27.3 Million for Fiscal First Quarter 2024

    TAMPA, FL / ACCESSWIRE / November 20, 2023 / Upexi, Inc. (NASDAQ:UPXI) (the "Company" or "Upexi"), a multi-faceted Amazon and Direct to Consumer brand owner and innovator in aggregation, today announced its financial results for the fiscal first quarter 2024 ending September 30, 2023."Revenue for our fiscal first quarter 2024 grew 144% year-over-year and 53.5% sequentially driven by growth in both branded products and re-commerce," commented CEO of Upexi, Allan Marshall. "While our cost cutting measures are now beginning to yield material year-over-year decreases in operating expenses as a percentage of revenue, we have also continued to invest significantly in the future growth of our brand

    11/20/23 4:05:00 PM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    Upexi Preannounces Revenue of $27.3 Million for Fiscal 2024 First Quarter and Reschedules Financial Results Conference Call for November 20th at 4:30 PM ET

    TAMPA, FL / ACCESSWIRE / November 14, 2023 / Upexi Inc. (NASDAQ:UPXI) (the "Company" or "Upexi"), a multi-faceted Amazon and Direct-to-Consumer brand owner and innovator in aggregation, today announced preliminary and unaudited financial results for the fiscal 2024 first quarter ended September 30, 2023.Based on a preliminary and unaudited review, the Company anticipates:Revenue of approximately $27.3 million, an increase of 136% year-over-year and 53.2% sequentially, and above the previously issue revenue guidance range of $26 million to $27 million.Adjusted EBITDA of approximately $700,000 as compared to an Adjusted EBITDA loss of approximately $525,000, approximately a $1.2 million improv

    11/14/23 9:00:00 AM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    Upexi Inc. Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Upexi Inc.

    SC 13G - UPEXI, INC. (0001775194) (Subject)

    5/31/23 7:05:10 PM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G filed by Upexi Inc.

    SC 13G - UPEXI, INC. (0001775194) (Subject)

    3/10/23 4:37:37 PM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G/A filed by Upexi Inc. (Amendment)

    SC 13G/A - UPEXI, INC. (0001775194) (Subject)

    3/10/23 4:36:56 PM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G/A filed by Upexi Inc. (Amendment)

    SC 13G/A - UPEXI, INC. (0001775194) (Subject)

    3/10/23 4:36:22 PM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care